What Is Retatrutide?

Visao Geral da Pesquisa

Retatrutide (LY3437943) is a first-in-class incretin-based triple hormone agonista do receptor developed by Eli Lilly and Company to address the limitations of current obesidade and diabetes tipo 2 therapeutics by simultaneamente engaging three distinct metabolic pathways. A molecula foi descrito(a) pela primeira vez by Coskun et al. in a 2022 publication in Cell Metabolism, detailing its discovery, mechanism, and proof of concept from modelos pre-clinicos through Phase 1 human data.[4]

Structurally, retatrutide is a 39-aminoacido synthetic peptide engineered from a GIP peptide backbone. It incorporates three non-coded aminoacido residues — two α-aminoisobutyric acid (Aib) residues at positions 2 and 20, and one α-methyl-L-leucine residue at position 13 — para aprimorar metabolic stability and ligacao ao receptor. A C20 fatty diacid moiety is conjugated at lysine-17 via an AEEA-γGlu linker, promoting albumin binding and extending the plasma meia-vida to aproximadamente 6 days, enabling convenient uma vez por semana subcutaneo(a) administration.[4][8]

The foundational therapeutic rationale for retatrutide rests no(a) hypothesis que simultaneamente activating receptors for GLP-1, GIP, and glucagon can produce superior metabolic outcomes comparado(a) a mono- or dual-agonista do receptors. GLP-1 receptor agonism suprime appetite and estimula secrecao de insulina; GIP receptor agonism aprimora the insulinotropic response and apoia lipid metabolismo; and criticamente, glucagon receptor agonism aumenta energy expenditure and drives lipolysis and hepatico(a) fatty acid oxidation — a mechanism absent from existing dual agonists like tirzepatide.[1][10][11]

Clinical trials demonstraram remarkable efficacy. The pivotal Phase 2 trial by Jastreboff et al. (2023) no(a) New England Journal of Medicine relatado(a) dose-dependente perda de peso in adults with obesidade, reaching up to 24.2% mean peso corporal reduction at 48 weeks com o(a) 12 mg dose — and perda de peso nao tinha plateaued at study conclusion.[1] A parallel Phase 2 trial by Rosenstock et al. (2023) in The Lancet demonstrated HbA1c reductions of up to -2.02% in participants with diabetes tipo 2.[2] Phase 3 results do(a) TRIUMPH program have desde confirmou estes achados, with data showing up to 28.7% mean perda de peso at 68 weeks and significant relief from obesidade-related comorbidities incluindo knee osteoartrite.[5]

Beyond obesidade and diabetes, retatrutide is under investigation for metabolic dysfunction-associated steatotic doenca hepatico(a)a (MASLD), onde a Phase 2a substudy by Sanyal et al. (2024) publicado(a) em Nature Medicine demonstrated que the 8 mg and 12 mg doses normalized liver fat (<5%) in over 85% of participants, with relative reductions of up to 86% em relacao ao basal.[3] Additional ongoing Phase 3 trials are evaluating the drug for desfechos cardiovasculares (TRIUMPH-OUTCOMES), cronico(a) doenca renal (TRANSCEND-CKD), obstructive sleep apnea, and knee osteoartrite.[5][7][9] Preclinical research tambem tem revelou intriguing potential in obesidade-associated cancer progression, with Marathe et al. (2025) demonstrating que retatrutide reduziu tumor engraftment and retardou tumor onset, outperforming semaglutide in tumor supressao.[14]